Founded in 2007, Genor Biopharma Co. Ltd (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer).
Genor Biopharma is creating a fully integrated and end-to-end biopharma innovation company based in China, with global reach. In San Francisco, the cutting-edge bispecific and multi-specific discovery platform (Antibody Therapeutics Inc.) engineers novel and highly differentiated therapeutic antibody candidates with display technology, computer-aided design, and site mutagenesis. The industry leading R&D center located in Shanghai focuses on CMC (Chemistry, Manufacturing, and Controls) development. This center is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance. In 2016, the GMP commercial manufacturing facility was built and commissioned in Yuxi, Yunan and is currently operating with a highly GMP compliant production team. This commercial facility employs advanced continuous-flow cell culture technologies for high yield manufacturing (~20 g/L) as well as internally-developed cell culture media for cost-effective production. The site produces Phase III and pivotal trial clinical supplies, executes the commercial process validation, and performs the commercial manufacturing after product launch.
Genor Biopharma currently has 10+ drug candidates under development in clinical or New Drug Application (NDA) stages. Among them, the NDA for Geptanolimab (GB226) has been granted for priority review by the Center for Drug Evaluation (CDE) and has successfully passed the NDA pre-approval inspection by the National Medical Products Administration (NMPA), with a product launch targeted for 2021. It is the first PD-1 inhibitor worldwide for peripheral T-cell lymphoma (PTCL) and is expected to bring safe and high-quality therapeutic benefits to patients. The NDA filing for Infliximab (GB242) has also been accepted by CDE and is currently under review by the agency.
Beijing office
Yuxi, Yunnan - Principally Phase 3 and commercial manufacturing
Zhangjiang, Shanghai - R&D center, QC/Analytical center, cGMP sample manufacturing
South San Francisco, US - Bi-specific platform
We aspire to become a biopharmaceutical company with global presence, serving patients and society.
Our mission is to become a biopharmaceutical engine in discovery, research, development, manufacturing and commercialization of innovative therapeutics initially for patients in China and gradually for patients globally.
Our History
December 2007
Genor Biopharma, our key operating subsidiary, was incorporated in Shanghai, PRC
October 2011
Shanghai Genor was incorporated in Shanghai, PRC
July 2013
We obtained IND approval for GB221 in PRC
July 2014
Yuxi Genor was incorporated in Yuxi, Yunnan, PRC
January 2015
We obtained IND approval for GB242 in PRC
April 2016
We completed the construction of manufacturing facilities in Yuxi, Yunnan, PRC
November 2016
We obtained IND approval for GB226 in PRC
April 2017
Our Company was incorporated in the Cayman Islands
December 2017
We obtained IND approval for GB223 in PRC
December 2018
Our Company completed Series A financing
September 2019
Our Company acquired 85% of the issued share capital in ABT
May 2020
Our Company completed Series B financing
June 2020
We in-licensed GB491 from G1 Therapeutics and GB492 from ImmuneSensor Therapeutics
July 2020
Our submission of an NDA for GB226 as a monotherapy in r/r PTCL in the PRC was accepted by NMPA and granted priority review status